JP2008534672A - 抗菌剤としての７−フルオロ−１，３−ジヒドロ−インドール−２−オンオキサゾリジノン - Google Patents
抗菌剤としての７−フルオロ−１，３−ジヒドロ−インドール−２−オンオキサゾリジノン Download PDFInfo
- Publication number
- JP2008534672A JP2008534672A JP2008504870A JP2008504870A JP2008534672A JP 2008534672 A JP2008534672 A JP 2008534672A JP 2008504870 A JP2008504870 A JP 2008504870A JP 2008504870 A JP2008504870 A JP 2008504870A JP 2008534672 A JP2008534672 A JP 2008534672A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- compound
- dihydro
- indol
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 15
- FFMDRLBKWBUTEW-UHFFFAOYSA-N 7-fluoro-1,3-dihydroindol-2-one;1,3-oxazolidin-2-one Chemical compound O=C1NCCO1.FC1=CC=CC2=C1NC(=O)C2 FFMDRLBKWBUTEW-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 119
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 32
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000186367 Mycobacterium avium Species 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 241000588621 Moraxella Species 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 208000001860 Eye Infections Diseases 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 241000295644 Staphylococcaceae Species 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- RYXZVPPFWXWUKQ-JTQLQIEISA-N methyl n-[[(5s)-3-(7-fluoro-1-methyl-2-oxo-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound O=C1O[C@@H](CNC(=O)OC)CN1C(C=C1F)=CC2=C1N(C)C(=O)C2 RYXZVPPFWXWUKQ-JTQLQIEISA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 241001112695 Clostridiales Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 145
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
- 238000002360 preparation method Methods 0.000 description 67
- 238000004128 high performance liquid chromatography Methods 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000007787 solid Substances 0.000 description 48
- -1 bicyclic oxazolidinone derivatives Chemical class 0.000 description 46
- 239000000203 mixture Substances 0.000 description 45
- 239000000243 solution Substances 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000012267 brine Substances 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 102000010909 Monoamine Oxidase Human genes 0.000 description 15
- 108010062431 Monoamine oxidase Proteins 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- SZKVETRZYWTMOM-UHFFFAOYSA-N 7-fluoro-1-methyl-5-nitro-3h-indol-2-one Chemical compound [O-][N+](=O)C1=CC(F)=C2N(C)C(=O)CC2=C1 SZKVETRZYWTMOM-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- HFKPSXLOLLNFRT-UHFFFAOYSA-N 2-(2,3-difluoro-5-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC([N+]([O-])=O)=CC(F)=C1F HFKPSXLOLLNFRT-UHFFFAOYSA-N 0.000 description 9
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- NWIUSWJEIXFMSG-UHFFFAOYSA-N 7-fluoro-1-methyl-3h-indol-2-one Chemical compound C1=CC(F)=C2N(C)C(=O)CC2=C1 NWIUSWJEIXFMSG-UHFFFAOYSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- MCVFFRWZNYZUIJ-UHFFFAOYSA-M lithium;trifluoromethanesulfonate Chemical compound [Li+].[O-]S(=O)(=O)C(F)(F)F MCVFFRWZNYZUIJ-UHFFFAOYSA-M 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- WMMMBCVEFLMOGE-SECBINFHSA-N (5r)-5-(aminomethyl)-3-(7-fluoro-1-methyl-2-oxo-3h-indol-5-yl)-1,3-oxazolidin-2-one Chemical compound C=1C(F)=C2N(C)C(=O)CC2=CC=1N1C[C@@H](CN)OC1=O WMMMBCVEFLMOGE-SECBINFHSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZBBGKXNNTNBRBH-LURJTMIESA-N tert-butyl n-[[(2s)-oxiran-2-yl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@H]1CO1 ZBBGKXNNTNBRBH-LURJTMIESA-N 0.000 description 5
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 4
- ZEHWERXBZDEZAK-UHFFFAOYSA-N 5-amino-7-fluoro-1-methyl-3h-indol-2-one Chemical compound NC1=CC(F)=C2N(C)C(=O)CC2=C1 ZEHWERXBZDEZAK-UHFFFAOYSA-N 0.000 description 4
- XWTUHLYJQKEZSI-UHFFFAOYSA-N 7-fluoro-1-methylindole-2,3-dione Chemical compound C1=CC(F)=C2N(C)C(=O)C(=O)C2=C1 XWTUHLYJQKEZSI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- HFCZWESSCLMEJE-UHFFFAOYSA-N 2-chloro-n-(2-fluoro-4-nitrophenyl)-n-methylacetamide Chemical compound ClCC(=O)N(C)C1=CC=C([N+]([O-])=O)C=C1F HFCZWESSCLMEJE-UHFFFAOYSA-N 0.000 description 3
- QOMGYYDCVLVQOT-UHFFFAOYSA-N 2-fluoro-n-methyl-4-nitroaniline Chemical compound CNC1=CC=C([N+]([O-])=O)C=C1F QOMGYYDCVLVQOT-UHFFFAOYSA-N 0.000 description 3
- ZFIQXJBQTKHTSF-UHFFFAOYSA-N 5-amino-7-fluoro-1-propan-2-yl-3h-indol-2-one Chemical compound NC1=CC(F)=C2N(C(C)C)C(=O)CC2=C1 ZFIQXJBQTKHTSF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- BBKRNGHRNVFYQT-LLVKDONJSA-N (5r)-5-(aminomethyl)-3-(7-fluoro-2-oxo-1-propan-2-yl-3h-indol-5-yl)-1,3-oxazolidin-2-one Chemical compound C=1C(F)=C2N(C(C)C)C(=O)CC2=CC=1N1C[C@@H](CN)OC1=O BBKRNGHRNVFYQT-LLVKDONJSA-N 0.000 description 2
- KNJVHJKQNARYNV-UHFFFAOYSA-N 1-propyl-3h-indol-2-one Chemical compound C1=CC=C2N(CCC)C(=O)CC2=C1 KNJVHJKQNARYNV-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KPRGYIYUMZKHHZ-UHFFFAOYSA-N 5-amino-1-(cyclopropylmethyl)-7-fluoro-3h-indol-2-one Chemical compound C1=2C(F)=CC(N)=CC=2CC(=O)N1CC1CC1 KPRGYIYUMZKHHZ-UHFFFAOYSA-N 0.000 description 2
- KRGYQBGVCHEXMT-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-fluoro-3h-indol-2-one Chemical compound C1=2C(F)=CC(N)=CC=2CC(=O)N1C1CC1 KRGYQBGVCHEXMT-UHFFFAOYSA-N 0.000 description 2
- HJSVRUHRUQTDKA-UHFFFAOYSA-N 5-amino-1-ethyl-7-fluoro-3h-indol-2-one Chemical compound NC1=CC(F)=C2N(CC)C(=O)CC2=C1 HJSVRUHRUQTDKA-UHFFFAOYSA-N 0.000 description 2
- DUDNCCHMZMFXSM-UHFFFAOYSA-N 5-amino-7-fluoro-1-propyl-3h-indol-2-one Chemical compound NC1=CC(F)=C2N(CCC)C(=O)CC2=C1 DUDNCCHMZMFXSM-UHFFFAOYSA-N 0.000 description 2
- VMUIOEOYZHJLEZ-UHFFFAOYSA-N 7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC=CC2=C1NC(=O)C2 VMUIOEOYZHJLEZ-UHFFFAOYSA-N 0.000 description 2
- HGKLNLYDMKJFCY-UHFFFAOYSA-N 7-fluoro-5-nitro-1-propan-2-yl-3h-indol-2-one Chemical compound [O-][N+](=O)C1=CC(F)=C2N(C(C)C)C(=O)CC2=C1 HGKLNLYDMKJFCY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YRQFKVAESZZKDZ-UHFFFAOYSA-N C(N)(OC(C)(C)C)=O.C(=O)(Cl)Cl Chemical compound C(N)(OC(C)(C)C)=O.C(=O)(Cl)Cl YRQFKVAESZZKDZ-UHFFFAOYSA-N 0.000 description 2
- FDAPSKCCSOCDQK-UHFFFAOYSA-N ClC(=O)OC.COC(N)=O Chemical compound ClC(=O)OC.COC(N)=O FDAPSKCCSOCDQK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000022760 infectious otitis media Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UYYHOFDZSUEAFV-CYBMUJFWSA-N tert-butyl n-[(2r)-3-[(1-ethyl-7-fluoro-2-oxo-3h-indol-5-yl)amino]-2-hydroxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@H](O)CNC1=CC(F)=C2N(CC)C(=O)CC2=C1 UYYHOFDZSUEAFV-CYBMUJFWSA-N 0.000 description 2
- HNRNBWFGROREEV-CQSZACIVSA-N tert-butyl n-[(2r)-3-[(7-fluoro-2-oxo-1-propyl-3h-indol-5-yl)amino]-2-hydroxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@H](O)CNC1=CC(F)=C2N(CCC)C(=O)CC2=C1 HNRNBWFGROREEV-CQSZACIVSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ZZECXSSUWZWZKH-GFCCVEGCSA-N (5r)-5-(aminomethyl)-3-[1-(cyclopropylmethyl)-7-fluoro-2-oxo-3h-indol-5-yl]-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](CN)CN1C(C=C1F)=CC2=C1N(CC1CC1)C(=O)C2 ZZECXSSUWZWZKH-GFCCVEGCSA-N 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OZEUJPGHXZHQCJ-UHFFFAOYSA-N 1-(2-fluoroethyl)-5-nitro-3h-indol-2-one Chemical compound [O-][N+](=O)C1=CC=C2N(CCF)C(=O)CC2=C1 OZEUJPGHXZHQCJ-UHFFFAOYSA-N 0.000 description 1
- RKMNEXJLXXTVNL-UHFFFAOYSA-N 1-(cyclopropylmethyl)-7-fluoro-5-nitro-3h-indol-2-one Chemical compound C1=2C(F)=CC([N+](=O)[O-])=CC=2CC(=O)N1CC1CC1 RKMNEXJLXXTVNL-UHFFFAOYSA-N 0.000 description 1
- DXZIOSALKTVICL-UHFFFAOYSA-N 1-cyclopropyl-7-fluoro-5-nitro-3h-indol-2-one Chemical compound C1=2C(F)=CC([N+](=O)[O-])=CC=2CC(=O)N1C1CC1 DXZIOSALKTVICL-UHFFFAOYSA-N 0.000 description 1
- VEEKTFHFMXGEEX-UHFFFAOYSA-N 1-ethyl-7-fluoroindole-2,3-dione 7-fluoro-1H-indole-2,3-dione Chemical compound FC=1C=CC=C2C(C(NC12)=O)=O.C(C)N1C(C(C2=CC=CC(=C12)F)=O)=O VEEKTFHFMXGEEX-UHFFFAOYSA-N 0.000 description 1
- KUAYAAWUJMDCAK-UHFFFAOYSA-N 1-ethyl-7-fluoroindole-2,3-dione;1-ethyl-7-fluoro-3h-indol-2-one Chemical compound C1=CC(F)=C2N(CC)C(=O)CC2=C1.C1=CC(F)=C2N(CC)C(=O)C(=O)C2=C1 KUAYAAWUJMDCAK-UHFFFAOYSA-N 0.000 description 1
- LVYJIIRJQDEGBR-UHFFFAOYSA-N 1-fluoro-2-iodoethane Chemical compound FCCI LVYJIIRJQDEGBR-UHFFFAOYSA-N 0.000 description 1
- SCRXASNUPJPFGP-UHFFFAOYSA-N 1-fluoro-3h-indol-2-one Chemical compound C1=CC=C2N(F)C(=O)CC2=C1 SCRXASNUPJPFGP-UHFFFAOYSA-N 0.000 description 1
- NACONAPBNNDYHF-UHFFFAOYSA-N 1-nitro-3h-indol-2-one Chemical compound C1=CC=C2N([N+](=O)[O-])C(=O)CC2=C1 NACONAPBNNDYHF-UHFFFAOYSA-N 0.000 description 1
- BXGYNKZNIBNJSW-UHFFFAOYSA-N 1-propan-2-yl-3h-indol-2-one Chemical compound C1=CC=C2N(C(C)C)C(=O)CC2=C1 BXGYNKZNIBNJSW-UHFFFAOYSA-N 0.000 description 1
- JTPFHCGGNVEZTF-UHFFFAOYSA-N 2,3-dihydro-1h-indole;1,3-oxazolidin-2-one Chemical class O=C1NCCO1.C1=CC=C2NCCC2=C1 JTPFHCGGNVEZTF-UHFFFAOYSA-N 0.000 description 1
- UXSQXUSJGPVOKT-UHFFFAOYSA-N 2-(2,3-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1F UXSQXUSJGPVOKT-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WVVWOMABVGXIRP-UHFFFAOYSA-N 3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-n-(2-methoxyethyl)propanamide Chemical compound O1C(CCC(=O)NCCOC)=NC(C=2C(=CC=CC=2)F)=N1 WVVWOMABVGXIRP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QQJDFBSOHQQLGC-UHFFFAOYSA-N 5-(aminomethyl)-3-phenyl-1,3-oxazolidin-2-one Chemical class O=C1OC(CN)CN1C1=CC=CC=C1 QQJDFBSOHQQLGC-UHFFFAOYSA-N 0.000 description 1
- NPEBIMGJPRYZLW-UHFFFAOYSA-N 5-amino-7-fluoro-1-(2-fluoroethyl)-3h-indol-2-one Chemical compound FC1=CC(N)=CC2=C1N(CCF)C(=O)C2 NPEBIMGJPRYZLW-UHFFFAOYSA-N 0.000 description 1
- JQCGHRDKVZPCRO-UHFFFAOYSA-N 5-nitro-1,3-dihydroindol-2-one Chemical compound [O-][N+](=O)C1=CC=C2NC(=O)CC2=C1 JQCGHRDKVZPCRO-UHFFFAOYSA-N 0.000 description 1
- DMNZTXPKDILDMO-UHFFFAOYSA-N 7-fluoro-1-(2-fluoroethyl)-3h-indol-2-one Chemical compound C1=CC(F)=C2N(CCF)C(=O)CC2=C1 DMNZTXPKDILDMO-UHFFFAOYSA-N 0.000 description 1
- KUQZKKKLHQNNHL-UHFFFAOYSA-N 7-fluoro-1-(2-fluoroethyl)indole-2,3-dione 7-fluoro-1H-indole-2,3-dione Chemical compound FC=1C=CC=C2C(C(NC12)=O)=O.FC=1C=CC=C2C(C(N(C12)CCF)=O)=O KUQZKKKLHQNNHL-UHFFFAOYSA-N 0.000 description 1
- HGBGVEOXPHGSOS-UHFFFAOYSA-N 7-fluoro-1h-indole-2,3-dione Chemical compound FC1=CC=CC2=C1NC(=O)C2=O HGBGVEOXPHGSOS-UHFFFAOYSA-N 0.000 description 1
- BKXHQZIHHAJWAS-UHFFFAOYSA-N 7-fluoro-5-nitro-1-propyl-3h-indol-2-one Chemical compound [O-][N+](=O)C1=CC(F)=C2N(CCC)C(=O)CC2=C1 BKXHQZIHHAJWAS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JODVKZBHHYJKTE-UHFFFAOYSA-N C(C)N1C(CC2=CC=CC(=C12)F)=O.C(C)N1C(CC2=CC(=CC(=C12)F)[N+](=O)[O-])=O Chemical compound C(C)N1C(CC2=CC=CC(=C12)F)=O.C(C)N1C(CC2=CC(=CC(=C12)F)[N+](=O)[O-])=O JODVKZBHHYJKTE-UHFFFAOYSA-N 0.000 description 1
- MUOFXUHFTOQDOX-GFCCVEGCSA-N C1(CC1)CN1C(CC2=CC(=CC(=C12)F)NC[C@H](CNC(O)=O)O)=O Chemical compound C1(CC1)CN1C(CC2=CC(=CC(=C12)F)NC[C@H](CNC(O)=O)O)=O MUOFXUHFTOQDOX-GFCCVEGCSA-N 0.000 description 1
- SBLLKTCZLMHRMU-LLVKDONJSA-N C1(CC1)N1C(CC2=CC(=CC(=C12)F)NC[C@H](CNC(O)=O)O)=O Chemical compound C1(CC1)N1C(CC2=CC(=CC(=C12)F)NC[C@H](CNC(O)=O)O)=O SBLLKTCZLMHRMU-LLVKDONJSA-N 0.000 description 1
- 0 CCN(C(C1)=O)c(c(F)c2)c1cc2NC1CC(*)*CC1 Chemical compound CCN(C(C1)=O)c(c(F)c2)c1cc2NC1CC(*)*CC1 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- HCLXGYVTEMUNQS-UHFFFAOYSA-N Cc1cc([N+]([O-])=O)cc(C2)c1NC2=O Chemical compound Cc1cc([N+]([O-])=O)cc(C2)c1NC2=O HCLXGYVTEMUNQS-UHFFFAOYSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- HGZVPNXSOSDVQY-UHFFFAOYSA-N FC=1C=CC=C2CC(N(C12)CCF)=O.FC=1C=C(C=C2CC(N(C12)CCF)=O)[N+](=O)[O-] Chemical compound FC=1C=CC=C2CC(N(C12)CCF)=O.FC=1C=C(C=C2CC(N(C12)CCF)=O)[N+](=O)[O-] HGZVPNXSOSDVQY-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GMMNRBBTJBUMNB-UHFFFAOYSA-N NC=1C=C2CC(N(C2=C(C1)F)CCF)=O.C(C)(C)(C)OC(N)=O Chemical compound NC=1C=C2CC(N(C2=C(C1)F)CCF)=O.C(C)(C)(C)OC(N)=O GMMNRBBTJBUMNB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- IMITYUVWVKDQNS-UHFFFAOYSA-N Nc(cc1F)cc(C2)c1NC2=O Chemical compound Nc(cc1F)cc(C2)c1NC2=O IMITYUVWVKDQNS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- XMQYIIPOGMQPOV-VKHMYHEASA-N [(2s)-oxiran-2-yl]methylcarbamic acid Chemical compound OC(=O)NC[C@H]1CO1 XMQYIIPOGMQPOV-VKHMYHEASA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- BCZQNQXJPMUTQA-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-1,2,4-oxadiazole-5-carboxylate Chemical compound O1C(C(=O)OCC)=NC(C=2C=CC(F)=CC=2)=N1 BCZQNQXJPMUTQA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YKNYRRVISWJDSR-GSVOUGTGSA-N methyl (2r)-oxirane-2-carboxylate Chemical compound COC(=O)[C@H]1CO1 YKNYRRVISWJDSR-GSVOUGTGSA-N 0.000 description 1
- KLLLRSBWNKVLPG-BYPYZUCNSA-N methyl n-[[(2s)-oxiran-2-yl]methyl]carbamate Chemical compound COC(=O)NC[C@H]1CO1 KLLLRSBWNKVLPG-BYPYZUCNSA-N 0.000 description 1
- AMTZJEAPUIQPIH-NSHDSACASA-N methyl n-[[(5s)-3-(1-ethyl-7-fluoro-2-oxo-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound C=1C(F)=C2N(CC)C(=O)CC2=CC=1N1C[C@H](CNC(=O)OC)OC1=O AMTZJEAPUIQPIH-NSHDSACASA-N 0.000 description 1
- PTQJFNLOPPGRLD-LBPRGKRZSA-N methyl n-[[(5s)-3-(7-fluoro-2-oxo-1-propan-2-yl-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound O=C1O[C@@H](CNC(=O)OC)CN1C(C=C1F)=CC2=C1N(C(C)C)C(=O)C2 PTQJFNLOPPGRLD-LBPRGKRZSA-N 0.000 description 1
- FDCDLZLKNZYUCJ-LBPRGKRZSA-N methyl n-[[(5s)-3-(7-fluoro-2-oxo-1-propyl-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound C=1C(F)=C2N(CCC)C(=O)CC2=CC=1N1C[C@H](CNC(=O)OC)OC1=O FDCDLZLKNZYUCJ-LBPRGKRZSA-N 0.000 description 1
- YLPKNGSLRUBDGA-NSHDSACASA-N methyl n-[[(5s)-3-[7-fluoro-1-(2-fluoroethyl)-2-oxo-3h-indol-5-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound O=C1O[C@@H](CNC(=O)OC)CN1C(C=C1F)=CC2=C1N(CCF)C(=O)C2 YLPKNGSLRUBDGA-NSHDSACASA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RNLNCLZTCBXFNZ-UHFFFAOYSA-N n-(2-fluorophenyl)pyrrolidine-1-carboxamide Chemical compound FC1=CC=CC=C1NC(=O)N1CCCC1 RNLNCLZTCBXFNZ-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YGCLIPSOSCUQIT-CQSZACIVSA-N tert-butyl n-[(2r)-3-[(1-cyclopropyl-7-fluoro-2-oxo-3h-indol-5-yl)amino]-2-hydroxypropyl]carbamate Chemical compound C1=2C(F)=CC(NC[C@@H](O)CNC(=O)OC(C)(C)C)=CC=2CC(=O)N1C1CC1 YGCLIPSOSCUQIT-CQSZACIVSA-N 0.000 description 1
- VBLBMUZMFMXIJD-OAHLLOKOSA-N tert-butyl n-[(2r)-3-[[1-(cyclopropylmethyl)-7-fluoro-2-oxo-3h-indol-5-yl]amino]-2-hydroxypropyl]carbamate Chemical compound C1=2C(F)=CC(NC[C@@H](O)CNC(=O)OC(C)(C)C)=CC=2CC(=O)N1CC1CC1 VBLBMUZMFMXIJD-OAHLLOKOSA-N 0.000 description 1
- SHRKLXHLIHIWNY-CYBMUJFWSA-N tert-butyl n-[(2r)-3-[[7-fluoro-1-(2-fluoroethyl)-2-oxo-3h-indol-5-yl]amino]-2-hydroxypropyl]carbamate Chemical compound FC1=CC(NC[C@@H](O)CNC(=O)OC(C)(C)C)=CC2=C1N(CCF)C(=O)C2 SHRKLXHLIHIWNY-CYBMUJFWSA-N 0.000 description 1
- WQSICRVEYPRROJ-LBPRGKRZSA-N tert-butyl n-[[(5s)-3-(7-fluoro-1-methyl-2-oxo-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound C=1C(F)=C2N(C)C(=O)CC2=CC=1N1C[C@H](CNC(=O)OC(C)(C)C)OC1=O WQSICRVEYPRROJ-LBPRGKRZSA-N 0.000 description 1
- LPLUWIGBFLNFPX-AWEZNQCLSA-N tert-butyl n-[[(5s)-3-(7-fluoro-2-oxo-1-propan-2-yl-3h-indol-5-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound C=1C(F)=C2N(C(C)C)C(=O)CC2=CC=1N1C[C@H](CNC(=O)OC(C)(C)C)OC1=O LPLUWIGBFLNFPX-AWEZNQCLSA-N 0.000 description 1
- ASWYDKGGNIWGIM-ZDUSSCGKSA-N tert-butyl n-[[(5s)-3-[7-fluoro-1-(2-fluoroethyl)-2-oxo-3h-indol-5-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate Chemical compound O=C1O[C@@H](CNC(=O)OC(C)(C)C)CN1C(C=C1F)=CC2=C1N(CCF)C(=O)C2 ASWYDKGGNIWGIM-ZDUSSCGKSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66871505P | 2005-04-06 | 2005-04-06 | |
| US68403305P | 2005-05-24 | 2005-05-24 | |
| PCT/IB2006/000954 WO2006106427A1 (en) | 2005-04-06 | 2006-03-27 | 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534672A true JP2008534672A (ja) | 2008-08-28 |
| JP2008534672A5 JP2008534672A5 (enExample) | 2009-05-14 |
Family
ID=36636389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504870A Withdrawn JP2008534672A (ja) | 2005-04-06 | 2006-03-27 | 抗菌剤としての７−フルオロ−１，３−ジヒドロ−インドール−２−オンオキサゾリジノン |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7435751B2 (enExample) |
| EP (1) | EP1869030A1 (enExample) |
| JP (1) | JP2008534672A (enExample) |
| KR (1) | KR20070108938A (enExample) |
| AP (1) | AP2007004172A0 (enExample) |
| AR (1) | AR053839A1 (enExample) |
| AU (1) | AU2006231919A1 (enExample) |
| BR (1) | BRPI0610533A2 (enExample) |
| CA (1) | CA2603899A1 (enExample) |
| CR (1) | CR9417A (enExample) |
| DO (1) | DOP2006000080A (enExample) |
| GT (1) | GT200600133A (enExample) |
| IL (1) | IL186119A0 (enExample) |
| MX (1) | MX2007012386A (enExample) |
| NL (1) | NL1031525C2 (enExample) |
| NO (1) | NO20075505L (enExample) |
| PE (1) | PE20061301A1 (enExample) |
| TN (1) | TNSN07373A1 (enExample) |
| TW (1) | TW200716101A (enExample) |
| UY (1) | UY29452A1 (enExample) |
| WO (1) | WO2006106427A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781643A1 (en) * | 2004-08-06 | 2007-05-09 | Pharmacia & Upjohn Company LLC | Oxindole oxazolidinones as antibacterial agents |
| KR100891485B1 (ko) | 2007-10-29 | 2009-04-02 | 주식회사 만도 | 디스크 브레이크의 주차브레이크 장치 |
| US20090124737A1 (en) * | 2007-11-12 | 2009-05-14 | Eastman Chemical Company | Acrylic plastisol viscosity reducers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164510A (en) | 1988-09-15 | 1992-11-17 | The Upjohn Company | 5'Indolinyl-5β-amidomethyloxazolidin-2-ones |
| ATE112773T1 (de) | 1988-09-15 | 1994-10-15 | Upjohn Co | 5-indolinyl-5-beta-amidomethyloxazolidin-2-one, 3-(substituierte kondensierte)phenyl-5-beta amidomethyloxazolidin-2-one und 3-(nitrogen- substituierte)phenyl-5-beta-amidomethyloxazolid n-2-one. |
| DE4425613A1 (de) | 1994-07-20 | 1996-01-25 | Bayer Ag | 5-gliedrige Heteroaryl-oxazolidinone |
| DE4425612A1 (de) | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
| US6015429A (en) * | 1994-09-08 | 2000-01-18 | Gore Enterprise Holdings, Inc. | Procedures for introducing stents and stent-grafts |
| DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
| DE19649095A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue Heteroaryl-Oxazolidinone |
| CN1288462A (zh) | 1998-01-23 | 2001-03-21 | 法玛西雅厄普约翰美国公司 | 噁唑烷酮组合库、组合物和制备方法 |
| CN1301248A (zh) | 1998-04-14 | 2001-06-27 | 三星精密化学株式会社 | 手性(s)－2,3－二取代－1－丙胺衍生物的制备方法 |
| AU1379900A (en) | 1998-11-17 | 2000-06-05 | Bayer Aktiengesellschaft | Novel substituted phenyloxazolidone derivatives |
| AU764980B2 (en) | 1998-11-27 | 2003-09-04 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| JP2003501351A (ja) | 1999-05-27 | 2003-01-14 | ファルマシア・アンド・アップジョン・カンパニー | 抗菌剤としての二環系オキサゾリジノン |
| ATE321024T1 (de) | 2000-10-17 | 2006-04-15 | Pharmacia & Upjohn Co Llc | Verfahren zur herstellung von oxazolidinonverbindungen |
| ES2268011T3 (es) | 2001-04-07 | 2007-03-16 | Astrazeneca Ab | Oxazolidinonas que contienen un grupo sulfonimida como antibioticos. |
| EP1380121B1 (en) | 2001-04-20 | 2007-09-26 | Pharmacia & Upjohn Company LLC | Process to prepare oxazolidinones |
| AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
| US7012088B2 (en) * | 2003-02-24 | 2006-03-14 | Pharmacia & Upjohn Company | Indolone oxazolidinones and derivatives thereof |
| EP1781643A1 (en) * | 2004-08-06 | 2007-05-09 | Pharmacia & Upjohn Company LLC | Oxindole oxazolidinones as antibacterial agents |
-
2006
- 2006-03-26 AU AU2006231919A patent/AU2006231919A1/en not_active Abandoned
- 2006-03-27 AP AP2007004172A patent/AP2007004172A0/xx unknown
- 2006-03-27 BR BRPI0610533-5A patent/BRPI0610533A2/pt not_active Application Discontinuation
- 2006-03-27 MX MX2007012386A patent/MX2007012386A/es unknown
- 2006-03-27 CA CA002603899A patent/CA2603899A1/en not_active Abandoned
- 2006-03-27 JP JP2008504870A patent/JP2008534672A/ja not_active Withdrawn
- 2006-03-27 EP EP06727519A patent/EP1869030A1/en not_active Withdrawn
- 2006-03-27 KR KR1020077022657A patent/KR20070108938A/ko not_active Ceased
- 2006-03-27 WO PCT/IB2006/000954 patent/WO2006106427A1/en not_active Ceased
- 2006-03-30 US US11/393,961 patent/US7435751B2/en not_active Expired - Fee Related
- 2006-04-04 TW TW095112018A patent/TW200716101A/zh unknown
- 2006-04-04 PE PE2006000363A patent/PE20061301A1/es not_active Application Discontinuation
- 2006-04-04 UY UY29452A patent/UY29452A1/es not_active Application Discontinuation
- 2006-04-04 AR ARP060101328A patent/AR053839A1/es unknown
- 2006-04-05 GT GT200600133A patent/GT200600133A/es unknown
- 2006-04-05 DO DO2006000080A patent/DOP2006000080A/es unknown
- 2006-04-05 NL NL1031525A patent/NL1031525C2/nl not_active IP Right Cessation
-
2007
- 2007-09-20 IL IL186119A patent/IL186119A0/en unknown
- 2007-10-05 CR CR9417A patent/CR9417A/es unknown
- 2007-10-05 TN TNP2007000373A patent/TNSN07373A1/fr unknown
- 2007-10-31 NO NO20075505A patent/NO20075505L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1869030A1 (en) | 2007-12-26 |
| TNSN07373A1 (fr) | 2009-03-17 |
| AR053839A1 (es) | 2007-05-23 |
| IL186119A0 (en) | 2008-01-20 |
| NL1031525C2 (nl) | 2007-01-30 |
| UY29452A1 (es) | 2006-11-30 |
| NL1031525A1 (nl) | 2006-10-09 |
| GT200600133A (es) | 2006-11-29 |
| DOP2006000080A (es) | 2006-12-15 |
| US7435751B2 (en) | 2008-10-14 |
| NO20075505L (no) | 2007-10-31 |
| AU2006231919A1 (en) | 2006-10-12 |
| BRPI0610533A2 (pt) | 2010-06-29 |
| KR20070108938A (ko) | 2007-11-13 |
| PE20061301A1 (es) | 2007-02-09 |
| TW200716101A (en) | 2007-05-01 |
| WO2006106427A8 (en) | 2007-12-06 |
| US20060229349A1 (en) | 2006-10-12 |
| CA2603899A1 (en) | 2006-10-12 |
| CR9417A (es) | 2007-12-04 |
| WO2006106427A1 (en) | 2006-10-12 |
| MX2007012386A (es) | 2007-11-07 |
| AP2007004172A0 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1899331B1 (en) | Homomorpholine oxazolidinones as antibacterial agents | |
| JP2008534672A (ja) | 抗菌剤としての７−フルオロ−１，３−ジヒドロ−インドール−２−オンオキサゾリジノン | |
| US20080262056A1 (en) | Oxindole Oxazolidinones as Antibacterial Agents | |
| JP2009500389A (ja) | 抗菌剤としてのアゼチジンおよびシクロブタンを含むオキサゾリジノンカルボキサミド | |
| JP2008521790A (ja) | 抗菌剤としてのチアゼピンオキサゾリジノン | |
| US20060229348A1 (en) | Oxindole oxazolidinone as antibacterial agent | |
| CN101155806A (zh) | 作为抗菌剂的羟吲哚唑烷酮 | |
| JP2009526036A (ja) | 抗菌剤としてのオキシインドールを含有するオキサゾリジノン | |
| JP2009525318A (ja) | 抗菌剤としてのベンズイソオキサゾールオキサゾリジノン | |
| CN101155805A (zh) | 作为抗菌剂的7－氟－1，3－二氢－吲哚－2－酮唑烷酮 | |
| KR20070030952A (ko) | 항바이러스제로서 옥신돌을 함유하는 옥사졸리딘온 | |
| JP2008521792A (ja) | 抗菌薬としてのジアゼピンオキサゾリジノン | |
| HK1104294A (en) | Oxazolidinones containing oxindoles as antibacterial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090318 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100712 |